Zobrazeno 1 - 2
of 2
pro vyhledávání: ''
Autor:
Jonas Jensen, Steen Jakobsen, Jørgen Frøkiær, L.H. Pedersen, Lise Wogensen, Niels Jessen, Ole Lajord Munk
Publikováno v:
EJNMMI Research
Pedersen, L H, Jensen, J B, Wogensen, L, Munk, O L, Jessen, N, Frøkiær, J & Jakobsen, S 2016, ' Renal PET-imaging with 11C-metformin in a transgenic mouse model for chronic kidney disease ', EJNMMI Research, vol. 6, 54 . https://doi.org/10.1186/s13550-016-0211-x
Pedersen, L H, Jensen, J B, Wogensen, L, Munk, O L, Jessen, N, Frøkiær, J & Jakobsen, S 2016, ' Renal PET-imaging with 11C-metformin in a transgenic mouse model for chronic kidney disease ', EJNMMI Research, vol. 6, 54 . https://doi.org/10.1186/s13550-016-0211-x
Organic cation transporters (OCTs) in the renal proximal tubule are important for the excretion of both exo- and endogenous compounds, and chronic kidney disease (CKD) alter the expression of OCT. Metformin is a well-known substrate for OCT, and rece
Autor:
Marijke Stigter-van Walsum, Gerd Stehle, Heiko G. Niessen, Egbert F. Smit, Paul Slobbe, Flavio Solca, Albert D. Windhorst, Guus A.M.S. van Dongen, Alex J. Poot
Publikováno v:
EJNMMI Research
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Slobbe, P, Windhorst, A D, Stigter-van Walsum, M, Smit, E F, Niessen, H G, Solca, F, Stehle, G, van Dongen, G A M S & Poot, A J 2015, ' A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [C-11]erlotinib and [F-18]afatinib in lung cancer-bearing mice ', EJNMMI Research, vol. 5, 14 . https://doi.org/10.1186/s13550-015-0088-0
EJNMMI Research, 5:14. Springer Berlin
Background Tyrosine kinase inhibitors (TKIs) have experienced a tremendous boost in the last decade, where more than 15 small molecule TKIs have been approved by the FDA. Unfortunately, despite their promising clinical successes, a large portion of p